Tissue Diagnostics Market is expected to Grow at CAGR of 8.54% through 2030
Rising adoption of immunohistochemistry (IHC) and growing
demand for digital pathology is expected to drive the Global Tissue Diagnostics
Market growth in the forecast period, 2026-2030.
According to TechSci Research report, “Tissue
Diagnostics Market – Global Industry Size, Share, Trends, Competition,
Forecast & Opportunities, 2020-2030F”, the Global Tissue Diagnostics Market
stood at USD 5.72 Billion in 2024 and is anticipated to reach USD 9.37 Billion with
a CAGR of 8.54% through 2030.
The rising adoption of immunohistochemistry (IHC) in
the global tissue diagnostics market is driven by its superior ability to
provide precise and targeted cancer diagnoses. IHC is widely recognized for its
effectiveness in detecting and localizing specific antigens in tissues through
the use of labeled antibodies. This technique has become an essential tool in
oncology, allowing pathologists to differentiate between cancer subtypes and
guide personalized treatment strategies. The increasing global burden of
cancer, coupled with the need for more accurate diagnostic tools, has propelled
the demand for IHC across healthcare institutions and diagnostic laboratories.
One of the key drivers of IHC adoption is its ability
to detect specific biomarkers, which are crucial in identifying tumor origin,
predicting disease progression, and determining appropriate therapeutic
options. For instance, IHC plays a vital role in detecting hormone receptors
such as estrogen and progesterone receptors in breast cancer, as well as
HER2/neu overexpression, which significantly influences treatment decisions.
Similarly, IHC helps in identifying markers such as PD-L1 in lung cancer, guiding
immunotherapy-based interventions. The growing emphasis on precision medicine,
which focuses on tailoring treatment plans based on individual patient
profiles, has further accelerated the adoption of IHC in clinical settings. Advancements
in IHC technology have also contributed to its increased utilization.
Innovations such as automated staining platforms, multiplex IHC assays, and
digital pathology integration have enhanced the efficiency and accuracy of
IHC-based diagnostics. Automation reduces human error, increases throughput,
and provides standardized results, making it a preferred choice for high-volume
laboratories. Furthermore, the integration of artificial intelligence (AI) with
digital pathology is enhancing the interpretation of IHC slides, enabling
quicker and more reliable diagnostic outcomes. The growing focus on early
cancer detection and the rising demand for minimally invasive diagnostic
techniques are also driving the uptake of IHC. Healthcare providers are
increasingly relying on IHC for detecting cancers at an early stage, allowing
for timely intervention and improved patient outcomes. Additionally,
pharmaceutical companies are leveraging IHC to support drug development and
companion diagnostics, further expanding its applications.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Tissue Diagnostics Market”
The Global Tissue Diagnostics Market is segmented into
product, application, technology, regional distribution, and company.
Based on Technology, the In the Global Tissue
Diagnostics Market, Immunohistochemistry (IHC) was the dominating segment among
Immunohistochemistry, In-Situ Hybridization (ISH), and Digital Pathology &
Workflow Management. IHC is widely used for diagnosing various cancers, including
breast, prostate, and gastric cancers, due to its ability to detect specific
antigens in tissue samples with high sensitivity and specificity. This
technique plays a crucial role in cancer prognosis, treatment planning, and
biomarker detection, making it an indispensable tool in pathology labs
worldwide.
The dominance of IHC is largely driven by the growing
demand for personalized medicine and targeted therapies, where identifying
protein expression in tumors is critical for selecting the most effective
treatment. Moreover, advancements in IHC reagents and automated staining
systems have significantly improved the accuracy, reproducibility, and
efficiency of the diagnostic process, further boosting its adoption. Additionally,
IHC is preferred over other techniques due to its relatively lower cost, ease
of implementation, and wide availability across healthcare settings, including
hospitals, diagnostic laboratories, and research institutions. The continuous
development of novel biomarkers and the integration of artificial intelligence
(AI) in image analysis are also enhancing the utility and accuracy of IHC in
tissue diagnostics. With the increasing prevalence of cancer worldwide and the
rising focus on early detection and precision medicine, IHC is expected to
maintain its leading position in the Global Tissue Diagnostics Market. Its
critical role in disease characterization and treatment decision-making ensures
its sustained dominance over other diagnostic techniques.
Based on region, Europe is the second dominating
region in the Global Tissue Diagnostics Market, driven by its advanced
healthcare infrastructure, high cancer incidence, and strong focus on early
disease detection and precision medicine. Countries such as Germany, the United
Kingdom, and France are at the forefront of tissue diagnostic advancements,
with well-established pathology networks and significant investments in cancer
research and diagnostic technologies. The rising burden of cancer across
Europe, particularly breast, lung, and colorectal cancers, has led to an
increasing demand for tissue-based diagnostic solutions. According to the
European Cancer Information System (ECIS), cancer cases continue to rise,
prompting governments and healthcare institutions to prioritize early screening
and accurate diagnosis. This has led to the widespread adoption of techniques
such as immunohistochemistry (IHC) and in-situ hybridization (ISH) across the
region.
Additionally, Europe's regulatory landscape, governed
by agencies such as the European Medicines Agency (EMA), ensures the
availability of high-quality diagnostic solutions, fostering trust and
widespread adoption in hospitals and laboratories. The region is also
witnessing a growing trend of automation and digital pathology, enhancing
efficiency and accuracy in diagnostic workflows. Collaborations between
research institutions and industry players, along with favorable reimbursement
policies and funding initiatives for cancer diagnostics, further contribute to
Europe's strong market position. With a growing aging population, increasing
awareness of cancer screening programs, and continuous technological
advancements, Europe is expected to maintain its position as the second-leading
region in the Global Tissue Diagnostics Market.
Major companies operating in Global Tissue
Diagnostics Market are:
- Nanoscribe
GmbH & Co. KG
- Stratasys
Ltd.
- 3D
Systems Inc.
- EOS
GmbH
- Renishaw
PLC
- Exone
Company.
- Formlabs
Inc.,
- Materialise
NV.
- SLM
Solutions Group AG
- Oxferd
Performance Materials, Inc.
Download Free Sample Report
Customers can also request for 10% free customization
on this report
“The Asia-Pacific region is witnessing significant
growth in the tissue diagnostics market, driven by a combination of
demographic, economic, and healthcare-related factors. The region is home to a
large and aging population, which is increasingly susceptible to chronic
diseases, including cancer. Rising cancer prevalence, fueled by lifestyle
changes, environmental factors, and improved disease awareness, is contributing
to the growing demand for advanced diagnostic solutions such as tissue
diagnostics. Countries like China, India, and Japan are experiencing a surge in
cancer cases, necessitating the expansion of diagnostic capabilities to
facilitate early detection and effective treatment planning. Economic development across the Asia-Pacific
region has also led to an increase in healthcare expenditure, with governments
and private sector entities investing in improving healthcare infrastructure
and access to advanced medical technologies. As healthcare facilities expand
and modernize, there is a growing emphasis on adopting high-precision
diagnostic techniques, such as immunohistochemistry (IHC) and in situ
hybridization (ISH), to enhance diagnostic accuracy. Furthermore, the
Asia-Pacific market offers lucrative opportunities for global tissue
diagnostics companies looking to establish a foothold in emerging economies.
Market players are increasingly focusing on strategic partnerships, mergers,
and acquisitions to tap into the region's potential. Favorable regulatory
reforms, increasing adoption of digital pathology, and rising healthcare
awareness further bolster market expansion in the Asia-Pacific region”, said
Mr. Karan Chechi, Research Director of TechSci Research, a research-based
management consulting firm.
“Tissue
Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and
Forecast, Segmented By Product
(Instruments, Reagents and Consumables),
By Application (Breast Cancer, Prostate Cancer, Gastric Cancer, Other Cancers),
By Technology (Immunohistochemistry, In-Situ Hybridizations, Digital Pathology
and Workflow Management, Others), By Region and Competition, 2020-2030F”, has evaluated the future growth potential of Global
Tissue Diagnostics Market and provides statistics & information on market
size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global Tissue
Diagnostics Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com